Open Payments

Yale-New Haven Hospital

Type
Teaching hospital
Where
New Haven, CT
Medicare CCN
070022
Received
$1,067,772 in 198 records, 2021 ($181,880 general, $885,892 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2021General payment65$181,880
2021Research payment133$885,892

By company

CompanyRecordsAmountYears
SEAGEN INC.63$383,9252021
CARDIVA MEDICAL, INC.2$120,0002021
Arrow International, Inc.2$93,4912021
Heron Therapeutics, Inc.13$87,9022021
TransMedics, Inc.9$46,4962021
ZOLL Circulation Inc11$45,1282021
Genentech USA, Inc.1$35,0002021
Omeros Corporation1$32,8742021
MAYNE PHARMA COMMERCIAL LLC2$32,7802021
Conformis, Inc.4$29,9992021
Orthofix Medical, Inc.8$21,2652021
Johnson & Johnson Health Care Systems Inc.7$19,6392021
E.R. Squibb & Sons, L.L.C.3$17,4502021
ClearPoint Neuro, Inc.1$13,8362021
SERVIER PHARMACEUTICALS LLC7$11,8762021
AstraZeneca Pharmaceuticals LP15$10,8342021
Sage Therapeutics, LLC6$8,7102021
Siemens Medical Solutions USA, Inc.4$8,2742021
VentureMed Group, Inc.2$7,7252021
Amgen Inc.1$5,0002021
Eisai Inc.1$5,0002021
Cardiovascular Systems Inc.4$4,1822021
Edwards Lifesciences Corporation3$4,1192021
Medical Device Business Services, Inc.2$3,6212021
Indivior Inc.4$3,2772021
Henry Schein, Inc.1$3,0002021
Stryker Corporation3$2,7862021
Merit Medical Systems Inc1$2,6802021
Mindray DS USA, Inc.5$2,3442021
Intersect ENT, Inc.1$1,8902021
PFIZER INC.1$1,4302021
Bio-Rad Laboratories, Inc.1$3262021
GE HEALTHCARE1$2832021
AngioDynamics, Inc.1$2202021
SANOFI US SERVICES INC.2$1532021
Regeneron Pharmaceuticals, Inc.1$1002021
Medline Industries LP1$742021
Boston Scientific Corporation1$502021
Eli Lilly and Company1$122021
Zimmer Biomet Holdings, Inc.1$112021

By nature of payment

NatureRecordsAmount
Research payment133$885,892
Space rental or facility fees (teaching hospital only)6$50,000
Gift12$45,139
Debt forgiveness13$23,558
Long term medical supply or device loan10$21,081
Grant5$21,071
Education1$10,000
Compensation for services other than consulting, including serving as faculty or as a speaker at a v2$8,000
Charitable Contribution16$3,027

Records

DateCompanyAmountNatureFormProductStudyYear
2021-12-31Omeros Corporation$32,874Research paymentCash or cash equivalentAn Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients2021
2021-12-31Siemens Medical Solutions USA, Inc.$6,750Research paymentCash or cash equivalentYale New Haven Hosp Constable Neuro Clinical MR2021
2021-12-31Edwards Lifesciences Corporation$3,471Long term medical supply or device loanIn-kind items and servicesHemoSphere Device, Hemodynamic Monitoring2021
2021-12-31Siemens Medical Solutions USA, Inc.$675Research paymentCash or cash equivalentYaleNewHavenHosp2019IPR925TurkBrowne2021
2021-12-31Edwards Lifesciences Corporation$364Long term medical supply or device loanIn-kind items and servicesHemoSphere Device, Hemodynamic Monitoring2021
2021-12-31Stryker Corporation$335Debt forgivenessCash or cash equivalent2021
2021-12-31Edwards Lifesciences Corporation$283Long term medical supply or device loanIn-kind items and servicesHemoSphere Device, Hemodynamic Monitoring2021
2021-12-31Siemens Medical Solutions USA, Inc.$149Research paymentCash or cash equivalentYale2021MRIPR022IPR023IPR024Mahajan2021
2021-12-31Medline Industries LP$74Debt forgivenessCash or cash equivalent2021
2021-12-22Sage Therapeutics, LLC$4,160Research paymentCash or cash equivalentA PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC2021
2021-12-22SEAGEN INC.$1,500Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2021
2021-12-22SEAGEN INC.$750Research paymentCash or cash equivalentA Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies2021
2021-12-17Orthofix Medical, Inc.$468Research paymentCash or cash equivalentM6-C Device, Prosthesis, Intervertebral DiscM6-C Post Approval Study (PAS)- CA-C0042021
2021-12-15SEAGEN INC.$9,953Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2021
2021-12-14SERVIER PHARMACEUTICALS LLC$390Research paymentCash or cash equivalentSTUDY OF AG-270 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA WITH MTAP LOSS2021
2021-12-13SERVIER PHARMACEUTICALS LLC$1,128Research paymentCash or cash equivalentSTUDY OF AG-270 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA WITH MTAP LOSS2021
2021-12-08SEAGEN INC.$4,044Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2021
2021-12-08Indivior Inc.$641Research paymentIn-kind items and servicesSUBLOCADE Drug, OUDCOORDINATING OPIOID USE TREATMENT THROUGH MEDICAL MANAGEMENT WITH INFECTION TREATMENT (PROJECT COMMIT)2021
2021-12-06Indivior Inc.$961Research paymentIn-kind items and servicesSUBLOCADE Drug, OUDLONG-ACTING BUPRENORPHINE VS. NALTREXONE OPIOID TREATMENTS IN CJS-INVOLVED ADULTS2021
2021-12-02SEAGEN INC.$9,204Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2021
2021-12-01Cardiovascular Systems Inc.$56Research paymentCash or cash equivalentDiamondback Coronary Device, Atherectomy DeviceECLIPSE2021
2021-11-23SEAGEN INC.$2,162Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2021
2021-11-23SEAGEN INC.$1,500Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2021
2021-11-17SEAGEN INC.$780Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2021
2021-11-10SEAGEN INC.$780Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2021
2021-11-10SEAGEN INC.$390Research paymentCash or cash equivalentPADCEV Biological, OncologyOpen-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without2021
2021-11-04Heron Therapeutics, Inc.$5,730Research paymentCash or cash equivalent DrugAprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)2021
2021-10-26CARDIVA MEDICAL, INC.$45,000Research paymentCash or cash equivalentCardiva VASCADE 5F VCS Device, DevicesVASCADE Device Outcomes2021
2021-10-20Eisai Inc.$5,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentFycompa Drug, Neurology2021
2021-10-20SEAGEN INC.$750Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2021
2021-10-19Orthofix Medical, Inc.$400Research paymentCash or cash equivalentM6-C Device, Prosthesis, Intervertebral DiscM6-C Post Approval Study (PAS)- CA-C0042021
2021-10-13SEAGEN INC.$4,092Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2021
2021-10-13SEAGEN INC.$3,702Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2021
2021-10-13SEAGEN INC.$1,580Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2021
2021-10-13SEAGEN INC.$1,050Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2021
2021-10-11SEAGEN INC.$7,500Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12021
2021-10-11SEAGEN INC.$4,000Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12021
2021-10-11SEAGEN INC.$2,929Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12021
2021-10-11SEAGEN INC.$1,170Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12021
2021-10-11SEAGEN INC.$937Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12021
2021-10-11SEAGEN INC.$550Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12021
2021-10-07Heron Therapeutics, Inc.$2,660Research paymentCash or cash equivalent DrugAprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)2021
2021-10-06SEAGEN INC.$9,350Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2021
2021-10-06SEAGEN INC.$9,223Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2021
2021-10-06SEAGEN INC.$2,598Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2021
2021-10-04AstraZeneca Pharmaceuticals LP$31Charitable ContributionCash or cash equivalent2021
2021-09-29Mindray DS USA, Inc.$1,020Long term medical supply or device loanCash or cash equivalentAG Module(O2/package/accessory) Device, MONITORING EQUIPMENT2021
2021-09-29Mindray DS USA, Inc.$1,020Long term medical supply or device loanCash or cash equivalentAG Module(O2/package/accessory) Device, MONITORING EQUIPMENT2021
2021-09-29Bio-Rad Laboratories, Inc.$326Debt forgivenessCash or cash equivalentElectrophoresis Reagents Device, Electrophoresis2021
2021-09-29Mindray DS USA, Inc.$102Long term medical supply or device loanCash or cash equivalentBeneLink Module package Device, MONITORING EQUIPMENT2021
2021-09-29Mindray DS USA, Inc.$100Long term medical supply or device loanCash or cash equivalentBeneLink Module package Device, MONITORING EQUIPMENT2021
2021-09-29Mindray DS USA, Inc.$100Long term medical supply or device loanCash or cash equivalentBeneLink Module package Device, MONITORING EQUIPMENT2021
2021-09-28Orthofix Medical, Inc.$1,500Research paymentCash or cash equivalentM6-C Device, Prosthesis, Intervertebral DiscRestore CLINICAL TRIAL CA-C002 (M6 IDE)2021
2021-09-23Sage Therapeutics, LLC$250Research paymentCash or cash equivalentA PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC2021
2021-09-22SEAGEN INC.$18,064Research paymentCash or cash equivalentPADCEV Biological, OncologyOpen-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without2021
2021-09-22ZOLL Circulation Inc$5,735GiftCash or cash equivalentTemperature Management System Device, Temperature Management2021
2021-09-22ZOLL Circulation Inc$5,220GiftCash or cash equivalentTemperature Management System Device, Temperature Management2021
2021-09-22ZOLL Circulation Inc$2,090GiftCash or cash equivalentTemperature Management System Device, Temperature Management2021
2021-09-21SEAGEN INC.$1,249Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2021
2021-09-21SEAGEN INC.$500Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2021
2021-09-21SEAGEN INC.$500Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2021
2021-09-20Johnson & Johnson Health Care Systems Inc.$2,256Debt forgivenessIn-kind items and services2021
2021-09-20SEAGEN INC.$1,500Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12021
2021-09-16ZOLL Circulation Inc$4,010GiftCash or cash equivalentTemperature Management System Device, Temperature Management2021
2021-09-16ZOLL Circulation Inc$4,010GiftCash or cash equivalentTemperature Management System Device, Temperature Management2021
2021-09-16ZOLL Circulation Inc$4,010GiftCash or cash equivalentTemperature Management System Device, Temperature Management2021
2021-09-16ZOLL Circulation Inc$4,010GiftCash or cash equivalentTemperature Management System Device, Temperature Management2021
2021-09-16ZOLL Circulation Inc$4,010GiftCash or cash equivalentTemperature Management System Device, Temperature Management2021
2021-09-16ZOLL Circulation Inc$4,010GiftCash or cash equivalentTemperature Management System Device, Temperature Management2021
2021-09-16ZOLL Circulation Inc$4,010GiftCash or cash equivalentTemperature Management System Device, Temperature Management2021
2021-09-16ZOLL Circulation Inc$4,010GiftCash or cash equivalentTemperature Management System Device, Temperature Management2021
2021-09-15Siemens Medical Solutions USA, Inc.$700Research paymentCash or cash equivalentYaleNewHavenHosp2016MRIPR1023Huber2021
2021-09-13AstraZeneca Pharmaceuticals LP$52Charitable ContributionCash or cash equivalent2021
2021-09-07E.R. Squibb & Sons, L.L.C.$2,250GrantCash or cash equivalent2021
2021-09-07E.R. Squibb & Sons, L.L.C.$200GrantCash or cash equivalent2021
2021-09-01AstraZeneca Pharmaceuticals LP$139Charitable ContributionCash or cash equivalent2021
2021-08-31AstraZeneca Pharmaceuticals LP$26Charitable ContributionCash or cash equivalent2021
2021-08-30Indivior Inc.$192Research paymentIn-kind items and servicesSUBLOCADE Drug, OUDCOORDINATING OPIOID USE TREATMENT THROUGH MEDICAL MANAGEMENT WITH INFECTION TREATMENT (PROJECT COMMIT)2021
2021-08-30AstraZeneca Pharmaceuticals LP$104Charitable ContributionCash or cash equivalent2021
2021-08-27AstraZeneca Pharmaceuticals LP$139Charitable ContributionCash or cash equivalent2021
2021-08-25GE HEALTHCARE$283Debt forgivenessCash or cash equivalent2021
2021-08-24Johnson & Johnson Health Care Systems Inc.$5,328Debt forgivenessIn-kind items and services2021
2021-08-24Johnson & Johnson Health Care Systems Inc.$4,950Debt forgivenessIn-kind items and services2021
2021-08-24Johnson & Johnson Health Care Systems Inc.$3,108Debt forgivenessIn-kind items and services2021
2021-08-18SEAGEN INC.$4,833Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2021
2021-08-18SEAGEN INC.$1,800Research paymentCash or cash equivalentA Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies2021
2021-08-17E.R. Squibb & Sons, L.L.C.$15,000GrantCash or cash equivalent2021
2021-08-16SEAGEN INC.$58,574Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12021
2021-08-14Conformis, Inc.$14,300Research paymentCash or cash equivalentiTotal CR Device, ORTHOPAEDIC KNEE IMPLANTSiTotal 12-0052021
2021-08-14Conformis, Inc.$2,439Research paymentCash or cash equivalentiTotal CR Device, ORTHOPAEDIC KNEE IMPLANTSiTotal 12-0052021
2021-08-12SEAGEN INC.$9,870Research paymentIn-kind items and servicesPADCEV Biological, OncologyOpen-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without2021
2021-08-12SEAGEN INC.$9,864Research paymentIn-kind items and servicesPADCEV Biological, OncologyOpen-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without2021
2021-08-12Heron Therapeutics, Inc.$1,500Research paymentCash or cash equivalent DrugAprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)2021
2021-08-11SEAGEN INC.$18,262Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2021
2021-08-11SEAGEN INC.$9,953Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2021
2021-08-11SEAGEN INC.$6,253Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2021
2021-08-11Amgen Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2021
2021-08-11AstraZeneca Pharmaceuticals LP$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentCALQUENCE Drug, Oncology2021
2021-08-11SEAGEN INC.$248Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2021
2021-08-11Boston Scientific Corporation$50Charitable ContributionCash or cash equivalent2021
2021-08-10AstraZeneca Pharmaceuticals LP$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentTAGRISSO Drug, Oncology2021
2021-08-10AstraZeneca Pharmaceuticals LP$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentIMFINZI Biological, Oncology2021
2021-08-06SEAGEN INC.$10,000EducationCash or cash equivalentADCETRIS Biological, Oncology2021
2021-08-01Medical Device Business Services, Inc.$3,021GrantCash or cash equivalent2021
2021-07-27Henry Schein, Inc.$3,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2021
2021-07-27SERVIER PHARMACEUTICALS LLC$2,750Research paymentCash or cash equivalentSTUDY OF AG-270 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA WITH MTAP LOSS2021
2021-07-27SERVIER PHARMACEUTICALS LLC$1,653Research paymentCash or cash equivalentSTUDY OF AG-270 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA WITH MTAP LOSS2021
2021-07-27SERVIER PHARMACEUTICALS LLC$390Research paymentCash or cash equivalentSTUDY OF AG-270 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA WITH MTAP LOSS2021
2021-07-26SERVIER PHARMACEUTICALS LLC$3,225Research paymentCash or cash equivalentSTUDY OF AG-270 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA WITH MTAP LOSS2021
2021-07-26SERVIER PHARMACEUTICALS LLC$2,340Research paymentCash or cash equivalentSTUDY OF AG-270 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA WITH MTAP LOSS2021
2021-07-26SEAGEN INC.$2,162Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2021
2021-07-26Indivior Inc.$1,482Research paymentIn-kind items and servicesSUBLOCADE Drug, OUDLONG-ACTING BUPRENORPHINE VS. NALTREXONE OPIOID TREATMENTS IN CJS-INVOLVED ADULTS2021
2021-07-26AstraZeneca Pharmaceuticals LP$104Charitable ContributionCash or cash equivalent2021
2021-07-22Arrow International, Inc.$7,500Research paymentCash or cash equivalentTurnpike Catheter Device, INTERVENTIONAL ACCESSCTO-PCI2021
2021-07-22Heron Therapeutics, Inc.$425Research paymentCash or cash equivalent DrugAprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)2021
2021-07-21SEAGEN INC.$1,200Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2021
2021-07-21SEAGEN INC.$750Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2021
2021-07-20PFIZER INC.$1,430Research paymentIn-kind items and servicesA PHASE 2 12 WEEK ADAPTIVE OPEN LABEL SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND PHARMACOK2021
2021-07-20AstraZeneca Pharmaceuticals LP$104Charitable ContributionCash or cash equivalent2021
2021-07-20AstraZeneca Pharmaceuticals LP$52Charitable ContributionCash or cash equivalent2021
2021-07-19AstraZeneca Pharmaceuticals LP$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2021
2021-07-08AstraZeneca Pharmaceuticals LP$26Charitable ContributionCash or cash equivalent2021
2021-07-07AstraZeneca Pharmaceuticals LP$52Charitable ContributionCash or cash equivalent2021
2021-06-28TransMedics, Inc.$3,500Research paymentCash or cash equivalentORGAN CARE SYSTEM Device, DEVICEDCD HEART CAP2021
2021-06-28TransMedics, Inc.$1,981Research paymentCash or cash equivalentORGAN CARE SYSTEM Device, DEVICEDCD HEART2021
2021-06-28TransMedics, Inc.$325Research paymentCash or cash equivalentORGAN CARE SYSTEM Device, DEVICEDCD HEART2021
2021-06-21Johnson & Johnson Health Care Systems Inc.$65Debt forgivenessIn-kind items and services2021
2021-06-18MAYNE PHARMA COMMERCIAL LLC$12,780Research paymentCash or cash equivalentTOLSURA Drug, INFECTIOUS DISEASE2021
2021-06-17SEAGEN INC.$1,732Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2021
2021-06-17Sage Therapeutics, LLC$1,300Research paymentCash or cash equivalentA PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC2021
2021-06-17Sage Therapeutics, LLC$1,200Research paymentCash or cash equivalentA PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC2021
2021-06-16SEAGEN INC.$22,937Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2021
2021-06-16SEAGEN INC.$1,800Research paymentCash or cash equivalentPADCEV Biological, OncologyOpen-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without2021
2021-06-10Heron Therapeutics, Inc.$1,151Research paymentCash or cash equivalentZynrelef Drug, Postoperative PainHerniorrhaphy Study for Opioid Elimination2021
2021-06-09SEAGEN INC.$24,919Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2021
2021-06-09VentureMed Group, Inc.$250Research paymentCash or cash equivalentFLEX Vessel Prep System Device, VascularFLEX-AV Registry2021
2021-06-05Conformis, Inc.$1,430Research paymentCash or cash equivalentiTotal CR Device, ORTHOPAEDIC KNEE IMPLANTSiTotal 12-0052021
2021-06-04SANOFI US SERVICES INC.$53Charitable ContributionCash or cash equivalent2021
2021-06-03TransMedics, Inc.$5,785Research paymentCash or cash equivalentORGAN CARE SYSTEM Device, DEVICEDCD HEART CAP2021
2021-06-01Orthofix Medical, Inc.$1,700Research paymentCash or cash equivalentM6-C Device, Prosthesis, Intervertebral DiscM6-C Post Approval Study (PAS)- CA-C0042021
2021-05-28Conformis, Inc.$11,830Research paymentCash or cash equivalentiTotal CR Device, ORTHOPAEDIC KNEE IMPLANTSiTotal 12-0052021
2021-05-27Stryker Corporation$1,670Research paymentCash or cash equivalentSURPASS EVOLVE Device, FLOW DIVERTEREVOLVE2021
2021-05-26Cardiovascular Systems Inc.$1,500Research paymentCash or cash equivalentDiamondback Coronary Device, Atherectomy DeviceECLIPSE2021
2021-05-26SEAGEN INC.$390Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2021
2021-05-26SEAGEN INC.$390Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2021
2021-05-25Heron Therapeutics, Inc.$19,237Research paymentCash or cash equivalent DrugAprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)2021
2021-05-24Johnson & Johnson Health Care Systems Inc.$3,270Debt forgivenessIn-kind items and services2021
2021-05-19VentureMed Group, Inc.$7,475Research paymentCash or cash equivalentFLEX Vessel Prep System Device, VascularFLEX-AV Registry2021
2021-05-14Cardiovascular Systems Inc.$2,470Research paymentCash or cash equivalentDiamondback Coronary Device, Atherectomy DeviceECLIPSE2021
2021-05-06Orthofix Medical, Inc.$8,060Research paymentCash or cash equivalentM6-C Device, Prosthesis, Intervertebral DiscRestore CLINICAL TRIAL CA-C002 (M6 IDE)2021
2021-05-04Eli Lilly and Company$12Research paymentIn-kind items and servicesPEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREA2021
2021-04-29Intersect ENT, Inc.$1,890Charitable ContributionIn-kind items and servicesPROPEL Device, Otolaryngology (Ear, Nose, Throat)2021
2021-04-28Arrow International, Inc.$85,991Research paymentCash or cash equivalentTurnpike Catheter Device, INTERVENTIONAL ACCESSCTO-PCI2021
2021-04-28SEAGEN INC.$390Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2021
2021-04-28AngioDynamics, Inc.$220Debt forgivenessIn-kind items and servicesAsclera Drug, VIT2021
2021-04-27SEAGEN INC.$2,360Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2021
2021-04-27SEAGEN INC.$2,162Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2021
2021-04-22Heron Therapeutics, Inc.$24,241Research paymentCash or cash equivalent DrugAprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)2021
2021-04-22Merit Medical Systems Inc$2,680Debt forgivenessCash or cash equivalentEmbosphere Microspheres Device, Radiology2021
2021-04-21Genentech USA, Inc.$35,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentActivase Biological, Metabolism & Primary Care2021
2021-04-15Sage Therapeutics, LLC$1,300Research paymentCash or cash equivalentA PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC2021
2021-04-15Sage Therapeutics, LLC$500Research paymentCash or cash equivalentA PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC2021
2021-04-15Orthofix Medical, Inc.$500Research paymentCash or cash equivalentM6-C Device, Prosthesis, Intervertebral DiscM6-C Post Approval Study (PAS)- CA-C0042021
2021-04-13Orthofix Medical, Inc.$837Research paymentCash or cash equivalentM6-C Device, Prosthesis, Intervertebral DiscM6-C Post Approval Study (PAS)- CA-C0042021
2021-04-12Cardiovascular Systems Inc.$156Research paymentCash or cash equivalentDiamondback Coronary Device, Atherectomy DeviceECLIPSE2021
2021-04-07SEAGEN INC.$28,820Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2021
2021-04-07SEAGEN INC.$260Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2021
2021-03-29SEAGEN INC.$500Research paymentCash or cash equivalentA phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-12021
2021-03-26TransMedics, Inc.$4,420Research paymentCash or cash equivalentORGAN CARE SYSTEM Device, DEVICEDCD HEART CAP2021
2021-03-26Heron Therapeutics, Inc.$500Research paymentCash or cash equivalent DrugAprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)2021
2021-03-18Orthofix Medical, Inc.$7,800Research paymentCash or cash equivalentM6-C Device, Prosthesis, Intervertebral DiscM6-C Post Approval Study (PAS)- CA-C0042021
2021-03-18Stryker Corporation$781Long term medical supply or device loanIn-kind items and servicesCHROMOPHARE F300 Device, COMMUNICATIONS2021
2021-03-17Heron Therapeutics, Inc.$5,015Research paymentCash or cash equivalent DrugAprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)2021
2021-03-17Johnson & Johnson Health Care Systems Inc.$661Debt forgivenessIn-kind items and services2021
2021-03-12CARDIVA MEDICAL, INC.$75,000Research paymentCash or cash equivalentCardiva VASCADE 5F VCS Device, DevicesVASCADE Device Outcomes2021
2021-03-11TransMedics, Inc.$6,305Research paymentCash or cash equivalentORGAN CARE SYSTEM Device, DEVICEDCD HEART2021
2021-03-04Heron Therapeutics, Inc.$11,851Research paymentCash or cash equivalent DrugAprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)2021
2021-03-04Medical Device Business Services, Inc.$600GrantCash or cash equivalent2021
2021-02-25TransMedics, Inc.$17,550Research paymentCash or cash equivalentORGAN CARE SYSTEM Device, DEVICEDCD HEART2021
2021-02-25TransMedics, Inc.$1,430Research paymentCash or cash equivalentORGAN CARE SYSTEM Device, DEVICEDCD HEART CAP2021
2021-02-24SEAGEN INC.$15,632Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2021
2021-02-24SEAGEN INC.$123Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2021
2021-02-22SEAGEN INC.$390Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2021
2021-02-21Regeneron Pharmaceuticals, Inc.$100Charitable ContributionCash or cash equivalent2021
2021-02-18Heron Therapeutics, Inc.$1,540Research paymentCash or cash equivalent DrugAprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)2021
2021-02-10SEAGEN INC.$390Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2021
2021-02-05MAYNE PHARMA COMMERCIAL LLC$20,000Research paymentCash or cash equivalentTOLSURA Drug, INFECTIOUS DISEASE2021
2021-02-03SEAGEN INC.$24,292Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2021
2021-02-03SEAGEN INC.$13,879Research paymentCash or cash equivalentPADCEV Biological, OncologyA single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva2021
2021-02-03SEAGEN INC.$260Research paymentCash or cash equivalentOpen Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors2021
2021-01-31Zimmer Biomet Holdings, Inc.$11GiftIn-kind items and servicesZimmer Biomet Instruments and Implants Device, General2021
2021-01-28Heron Therapeutics, Inc.$750Research paymentCash or cash equivalent DrugAprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)2021
2021-01-27SEAGEN INC.$1,500Research paymentCash or cash equivalentPADCEV Biological, OncologyA Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che2021
2021-01-25SEAGEN INC.$4,716Research paymentCash or cash equivalentTUKYSA Drug, OncologyPhase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib2021
2021-01-15SANOFI US SERVICES INC.$100Charitable ContributionCash or cash equivalent2021
2021-01-14TransMedics, Inc.$5,200Research paymentCash or cash equivalentORGAN CARE SYSTEM Device, DEVICEDCD HEART CAP2021
2021-01-07Heron Therapeutics, Inc.$13,300Research paymentCash or cash equivalent DrugAprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)2021
2021-01-01ClearPoint Neuro, Inc.$13,836Long term medical supply or device loanIn-kind items and servicesClearPoint Neuro Workstation Device, Neurology2021

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

South Central Connecticut Planning RegionNew Haven city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In New Haven, CT, county South Central Connecticut Planning Region, CT, state Connecticut; placed by its city name.

MeasurePlace (city or town)
New Haven, CT
County
South Central Connecticut Planning Region, CT
State
Connecticut
Population B01003134,349570,5983,624,508
Population, 2020 census P1134,023-3,605,944
Median age B0100231.940.241.1
Under 18 B0100121.3%19.6%20.2%
65 and over B0100111.8%18.6%18.5%
Households B1100154,773230,6731,434,007
Foreign born B0500218.0%13.7%15.7%
Median household income B19013$56,851$88,197$95,781
Median family income B19113$68,668$115,384$122,706
Per capita income B19301$36,242$49,766$55,915
Poverty rate B1700123.9%11.4%10.0%
Unemployment rate B230258.4%6.0%5.6%
Civilian labor force B2302569,528307,6071,959,490
Mean commute (minutes) B0801321.523.526.5
Bachelor's degree or higher B1500338.9%42.0%42.5%
Housing units B2500160,333248,2671,541,822
Owner-occupied B2500328.4%60.5%66.5%
Renters B2500371.6%39.5%33.5%
Median home value B25077$287,100$353,100$366,900
Median gross rent B25064$1,488$1,525$1,488
White, not Hispanic B0300230.0%58.5%61.9%
Black B0300227.6%13.0%9.8%
Hispanic or Latino B0300231.0%19.5%18.3%
Asian B030025.2%4.5%4.7%
American Indian and Alaska Native B030020.2%0.1%0.1%

Economy now FRED unemployment 5.1% in Sep 2026 (4.2% a year earlier); per capita personal income $102,307 in 2025, up 33% in five years (+7.1% after inflation); Unemployment rate: 4.7% in Sep 2016 to 5.1% in Sep 2026; low 3.1%, high 11.9% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New Haven, CT.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.